UBT-251

N/A

Report date: 2026/05/22 20:01:29
NME

Base Information

Drug NameUBT-251
Drug Alias NameUBT251UBT-251
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsGlucagon receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucagon receptorGlucose-Dependent Insulinotropic Polypeptide Receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesLianbang Biotechnology (Zhuhai Hengqin) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNovo Nordisk A/SLianbang Biotechnology (Zhuhai Hengqin) Co Ltd
Inactive CompaniesN/A
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A